Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) saw a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 10,500 shares, an increase of 69.4% from the May 15th total of 6,200 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily volume of 5,200 shares, the days-to-cover ratio is presently 2.0 days.

Anebulo Pharmaceuticals Stock Performance

Shares of ANEB opened at $2.10 on Friday. The firm has a market cap of $54.45 million, a price-to-earnings ratio of -5.68 and a beta of -1.09. The stock has a 50 day moving average of $2.51 and a 200-day moving average of $2.52. Anebulo Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $4.05.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last announced its earnings results on Wednesday, May 15th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.05. On average, sell-side analysts predict that Anebulo Pharmaceuticals will post -0.47 earnings per share for the current fiscal year.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.